Total Payments
$45,637
2024 Payments
$119.15
Companies
6
Transactions
48
Medicare Patients
873
Medicare Billing
$246,553
Payment Breakdown by Category
Travel$38,728 (84.9%)
Consulting$5,143 (11.3%)
Food & Beverage$1,356 (3.0%)
Education$409.88 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $38,728 | 15 | 84.9% |
| Consulting Fee | $5,143 | 2 | 11.3% |
| Food and Beverage | $1,356 | 29 | 3.0% |
| Education | $409.88 | 2 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $39,825 | 40 | $0 (2023) |
| Eisai Inc. | $5,542 | 3 | $0 (2020) |
| AstraZeneca UK Limited | $135.00 | 1 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $100.00 | 2 | $0 (2024) |
| BioNTech SE | $19.15 | 1 | $0 (2024) |
| GlaxoSmithKline, LLC. | $15.94 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $119.15 | 3 | AstraZeneca Pharmaceuticals LP ($100.00) |
| 2023 | $160.68 | 2 | AstraZeneca UK Limited ($135.00) |
| 2022 | $15.94 | 1 | GlaxoSmithKline, LLC. ($15.94) |
| 2021 | $10.87 | 1 | Merck Sharp & Dohme Corporation ($10.87) |
| 2020 | $399.01 | 1 | Eisai Inc. ($399.01) |
| 2019 | $9,551 | 13 | Merck Sharp & Dohme Corporation ($9,551) |
| 2018 | $30,237 | 25 | Merck Sharp & Dohme Corporation ($30,237) |
| 2017 | $5,143 | 2 | Eisai Inc. ($5,143) |
All Payment Transactions
48 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/03/2024 | BioNTech SE | — | Food and Beverage | In-kind items and services | $19.15 | General |
| 05/31/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $75.00 | General |
| 05/31/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 10/23/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $25.68 | General |
| Category: ONCOLOGY | ||||||
| 06/02/2023 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 02/10/2022 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $15.94 | General |
| Category: ONCOLOGY | ||||||
| 01/31/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Education | In-kind items and services | $10.87 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2020 | Eisai Inc. | Lenvima (Drug) | Education | Cash or cash equivalent | $399.01 | General |
| Category: Oncology | ||||||
| 11/15/2019 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | In-kind items and services | $272.34 | General |
| 11/15/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $40.19 | General |
| 11/15/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $18.09 | General |
| 11/14/2019 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | In-kind items and services | $8,116.75 | General |
| 11/03/2019 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Food and Beverage | In-kind items and services | $46.79 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $55.43 | General |
| Category: ONCOLOGY | ||||||
| 03/28/2019 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Travel and Lodging | In-kind items and services | $87.12 | General |
| Category: ONCOLOGY | ||||||
| 03/28/2019 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 03/28/2019 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: ONCOLOGY | ||||||
| 03/28/2019 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Food and Beverage | In-kind items and services | $10.00 | General |
| Category: ONCOLOGY | ||||||
| 03/27/2019 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Travel and Lodging | In-kind items and services | $602.52 | General |
| Category: ONCOLOGY | ||||||
| 03/27/2019 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Travel and Lodging | In-kind items and services | $214.25 | General |
| Category: ONCOLOGY | ||||||
| 03/27/2019 | Merck Sharp & Dohme Corporation | LENVIMA (Drug) | Food and Beverage | In-kind items and services | $47.00 | General |
| Category: ONCOLOGY | ||||||
| 09/14/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $65.40 | General |
| Category: ONCOLOGY | ||||||
| 09/14/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $46.71 | General |
| Category: ONCOLOGY | ||||||
| 09/13/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $11,247.12 | General |
| Category: ONCOLOGY | ||||||
| 09/13/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $163.85 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 158 | 540 | $301,800 | $47,694 |
| 2022 | 4 | 205 | 669 | $370,355 | $58,300 |
| 2021 | 5 | 238 | 885 | $483,105 | $79,927 |
| 2020 | 5 | 272 | 840 | $413,815 | $60,633 |
Total Patients
873
Total Services
2,934
Medicare Billing
$246,553
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 122 | 483 | $263,235 | $40,654 | 15.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 19 | 40 | $20,800 | $4,266 | 20.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $17,765 | $2,774 | 15.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 138 | 558 | $304,110 | $47,508 | 15.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 16 | 48 | $25,200 | $4,481 | 17.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 26 | 26 | $27,170 | $4,440 | 16.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 25 | 37 | $13,875 | $1,871 | 13.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 160 | 752 | $409,840 | $67,230 | 16.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 23 | 74 | $37,370 | $7,037 | 18.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 21 | 21 | $21,945 | $3,320 | 15.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 19 | 23 | $8,625 | $1,338 | 15.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 15 | 15 | $5,325 | $1,002 | 18.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 156 | 669 | $347,880 | $47,058 | 13.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 26 | 57 | $28,215 | $5,435 | 19.3% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 55 | 79 | $11,455 | $3,778 | 33.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 22 | 22 | $21,780 | $3,489 | 16.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 13 | 13 | $4,485 | $871.59 | 19.4% |
About Dr. Vicky Makker, MD
Dr. Vicky Makker, MD is a Hematology & Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/30/2008. The National Provider Identifier (NPI) number assigned to this provider is 1972769800.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vicky Makker, MD has received a total of $45,637 in payments from pharmaceutical and medical device companies, with $119.15 received in 2024. These payments were reported across 48 transactions from 6 companies. The most common payment nature is "Travel and Lodging" ($38,728).
As a Medicare-enrolled provider, Makker has provided services to 873 Medicare beneficiaries, totaling 2,934 services with total Medicare billing of $246,553. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location New York, NY
- Active Since 07/30/2008
- Last Updated 06/16/2010
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1972769800
Products in Payments
- KEYTRUDA (Biological) $30,329
- Lenvima (Drug) $5,542
- LENVIMA (Drug) $1,049
- ZEJULA (Drug) $15.94
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New York
Jeffrey Zwicker, M.d, M.D
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Manuel Hidalgo Medina, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Ahmed Sawas, M.d, M.D
Hematology & Oncology — Payments: $807,524
Hematology & Oncology $807,524
Ruben Niesvizky, Md, MD
Hematology & Oncology — Payments: $734,512
Hematology & Oncology $734,512
Jeffrey Laurence, Md, MD
Hematology & Oncology — Payments: $706,018
Hematology & Oncology $706,018
Dr. Joshua Sabari, M.d, M.D
Hematology & Oncology — Payments: $603,205
Hematology & Oncology $603,205